Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2770974 | 0.93 | NR1H4 (0.43) | PPARANR1H4SMN1; SMN2MAOB | |
| SCHEMBL2772424 | 0.90 | NR1H4 (0.40) | KDM4EPPARANR1H4RXRARXRB | |
| SCHEMBL2771535 | 0.87 | PPARA (0.39) | KDM4EPPARANR1H4RXRARXRB | |
| SCHEMBL2771740 | 0.87 | KDM4E (0.40) | KDM4ENR1H4RXRARXRBRXRG | |
| SCHEMBL2773384 | 0.85 | TRPM8 (0.40) | PPARANR1H4RXRARXRBRXRG | |
| SCHEMBL2770877 | 0.85 | NR1H4 (0.42) | PPARANR1H4RXRARXRBRXRG | |
| SCHEMBL2773167 | 0.84 | NR1H4 (0.47) | KDM4EPPARANR1H4RXRARXRB | |
| SCHEMBL2772321 | 0.83 | NR1H4 (0.44) | PPARANR1H4MAOB | |
| SCHEMBL2770618 | 0.82 | NR1H4 (0.58) | KDM4EPPARANR1H4SMN1; SMN2KMT2A | |
| SCHEMBL2769939 | 0.81 | NR1H4 (0.41) | PPARANR1H4RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029547-B1 | FXR AGONISTS | LILLY CO ELI (US) | 2010-04-28 | — | — | EP | claimed |
| US-20090270460-A1 | FXR AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-10-29 | — | — | US | claimed |
| EP-2029547-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | claimed |
| WO-2007140183-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | claimed |
| EP-2029547-B1 | FXR AGONISTS | LILLY CO ELI (US) | 2010-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270460-A1 | FXR AGONISTS | NR1H4, SLC10A1, GPBAR1 | KDM4E 4469/4885PPARA 38/4885NR1H4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.